Documents

Oral pill vaccine platform advances with strong clinical data and extended financial runway.

Revenue surged and net income turned positive as clinical milestones and funding flexibility advanced.

Oral vaccine platform advances with global partnerships, cost savings, and key data milestones ahead.

Oral pill vaccine platform advances with key COVID-19 and norovirus milestones and Sanofi partnership.

Oral pill vaccine platform advances with pivotal trials and strong financial runway into 2027.

Oral pill vaccines show promise for broad, convenient immunization, with pivotal trial results due in 2026.

Oral pill vaccine platform shows broad efficacy and strong pipeline, with major milestones ahead.

2025 revenue soared to $237.3M, with pivotal vaccine trials and major partnerships advancing.

Dynavax partnership boosts cash runway and validates oral vaccine platform amid strong Q3 results.

Oral pill vaccine platform advances norovirus and COVID-19 trials, targeting 2026 milestones.

Q2 revenue surged, pipeline advanced, and Nasdaq relisting efforts intensified amid funding needs.

Director elections approved, reverse split and say-on-pay failed, partnership talks ongoing.

Second-generation oral norovirus vaccine shows strong immunogenicity and safety in phase I.

Oral vaccine platform advances with major COVID-19 trial, norovirus data, and strong partnership interest.

Q1 revenue rose sharply as COVID-19 trial resumed and norovirus program advanced.

Oral vaccine platform advances with BARDA-backed COVID-19 and promising norovirus programs.